571 related articles for article (PubMed ID: 21662976)
1. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A
Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976
[TBL] [Abstract][Full Text] [Related]
2. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
[TBL] [Abstract][Full Text] [Related]
3. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
Alshoukr F; Rosant C; Maes V; Abdelhak J; Raguin O; Burg S; Sarda L; Barbet J; Tourwé D; Pelaprat D; Gruaz-Guyon A
Bioconjug Chem; 2009 Aug; 20(8):1602-10. PubMed ID: 19610615
[TBL] [Abstract][Full Text] [Related]
4. Preclinical PET Imaging of NTSR-1-Positive Tumors with
Li D; Minnix M; Allen R; Bading J; Chea J; Wong P; Bowles N; Poku E; Shively JE
Cancer Biother Radiopharm; 2021 Oct; 36(8):651-661. PubMed ID: 32822229
[No Abstract] [Full Text] [Related]
5.
Wu W; Yu F; Zhang P; Bu T; Fu J; Ai S; You Q; Shi L; Shao G; Wang F; Hodolic M; Guo H
J Nucl Med; 2022 Sep; 63(9):1394-1400. PubMed ID: 35177423
[TBL] [Abstract][Full Text] [Related]
6. Evidence of
Marenco M; Lodola L; Persico MG; Frangipane V; Facoetti A; Aprile C; Hodolič M
Curr Pharm Biotechnol; 2018; 19(9):754-759. PubMed ID: 30160211
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Evaluation of
Prignon A; Provost C; Alshoukr F; Wendum D; Couvelard A; Barbet J; Forgez P; Talbot JN; Gruaz-Guyon A
Mol Pharm; 2019 Jun; 16(6):2776-2784. PubMed ID: 31013092
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of peptide-based imaging agents [
Zhang-Yin J; Provost C; Cancel-Tassin G; Rusu T; Penent M; Radulescu C; Comperat E; Cussenot O; Montravers F; Renard-Penna R; Talbot JN; Prignon A
Nucl Med Biol; 2020; 84-85():88-95. PubMed ID: 32251995
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Evaluation of 64Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor.
Deng H; Wang H; Wang M; Li Z; Wu Z
Mol Pharm; 2015 Aug; 12(8):3054-61. PubMed ID: 26162008
[TBL] [Abstract][Full Text] [Related]
11. (18)F- and (68)Ga-Labeled Neurotensin Peptides for PET Imaging of Neurotensin Receptor 1.
Maschauer S; Einsiedel J; Hübner H; Gmeiner P; Prante O
J Med Chem; 2016 Jul; 59(13):6480-92. PubMed ID: 27336295
[TBL] [Abstract][Full Text] [Related]
12. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Biological Evaluation of
Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
15. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET.
Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F
Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818
[TBL] [Abstract][Full Text] [Related]
16. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
Achilefu S; Srinivasan A; Schmidt MA; Jimenez HN; Bugaj JE; Erion JL
J Med Chem; 2003 Jul; 46(15):3403-11. PubMed ID: 12852770
[TBL] [Abstract][Full Text] [Related]
17. Syntheses, receptor bindings, in vitro and in vivo stabilities and biodistributions of DOTA-neurotensin(8-13) derivatives containing β-amino acid residues - a lesson about the importance of animal experiments.
Sparr C; Purkayastha N; Yoshinari T; Seebach D; Maschauer S; Prante O; Hübner H; Gmeiner P; Kolesinska B; Cescato R; Waser B; Reubi JC
Chem Biodivers; 2013 Dec; 10(12):2101-21. PubMed ID: 24327436
[TBL] [Abstract][Full Text] [Related]
18. PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.
Roosenburg S; Laverman P; Joosten L; Cooper MS; Kolenc-Peitl PK; Foster JM; Hudson C; Leyton J; Burnet J; Oyen WJ; Blower PJ; Mather SJ; Boerman OC; Sosabowski JK
Mol Pharm; 2014 Nov; 11(11):3930-7. PubMed ID: 24992368
[TBL] [Abstract][Full Text] [Related]
19. Five Stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumors.
Janssen PJ; de Visser M; Verwijnen SM; Bernard BF; Srinivasan A; Erion JL; Breeman WA; Vulto AG; Krenning EP; de Jong M
Cancer Biother Radiopharm; 2007 Jun; 22(3):374-81. PubMed ID: 17651043
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.
Jia Y; Shi W; Zhou Z; Wagh NK; Fan W; Brusnahan SK; Garrison JC
Nucl Med Biol; 2015 Nov; 42(11):816-23. PubMed ID: 26302836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]